▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

ImmunityBio (NASDAQ: IBRX)

$2.25

(-2.6%)

-$0.06

Price as of August 25, 2025, 4:00 p.m. ET

ImmunityBio Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
IBRX	-47.06%	-69.55%	-21.17%	-94%
S&P	+16.09%	+90.36%	+13.72%	+65%

ImmunityBio Company Info

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

News & Analysis

Featured Article

IBRX Sales Soar 2,540%

Motley Fool Markets Team | Aug 5, 2025

Featured Article

Why Shares of ImmunityBio Jumped This Week

The company's founder is spending his own money to help finance the business's efforts.

James Halley | Sep 15, 2023

Why Shares of ImmunityBio Were Up on Wednesday

James Halley | Jul 19, 2023

The company announced progress in two clinical trials.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services